2 research outputs found
Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy
The
stability of the connection between the antibody and the toxin
can have a profound impact on ADC safety and efficacy. There has been
increasing evidence in recent years that maleimide-based ADCs are
prone to payload loss via a retro-Michael type reaction. Herein, we
report a mild method for the hydrolysis of the succinimide-thioether
ring which results in a “ring-opened” linker. ADCs containing
this hydrolyzed succinimide linker show equivalent cytotoxicity, improved <i>in vitro</i> stability, improved PK exposure, and improved efficacy
as compared to their nonhydrolyzed counterparts. This method offers
a simple way to improve the stability, exposure, and efficacy of maleimide-based
ADCs
Determination of Antibody–Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation
Antibody-drug conjugates
(ADC) are currently an active area of
research, focused primarily on oncology therapeutics, but also to
a limited extent on other areas such as infectious disease. The success
of this type of targeted drug delivery is dependent upon many factors,
one of which is the performance of the linker in releasing an active
drug moiety under the appropriate conditions. As a tool in the development
of linker/payload chemistry, we have developed an in vitro method
for the identification of payload species released from ADCs in the
presence of lysosomal enzymes. This method utilizes commercially available
human liver S9 fraction as the source of these enzymes, and this has
certain advantages over lysosomal fractions or purified enzymes. This
article describes the characterization and performance of this assay
with multiple ADCs composed of known and novel linkers and payloads.
Additionally, we report the observation of incomplete degradation
of mAb protein chains by lysosomal enzymes in vitro, believed to be
the first report of this phenomenon involving an ADC therapeutic